Point-of-care procalcitonin testing

Topic Status Complete

Health Technology Wales researchers searched for evidence on the clinical and cost effectiveness of point-of-care procalcitonin testing in the assessment and treatment of sepsis in children. Health Technology Wales’ Assessment Group concluded to progress this topic to Evidence Appraisal.

Outcome of the appraisal

 

The Health Technology Wales Assessment Group concluded that there is currently insufficient evidence about the outcomes of procalcitonin point-of-care testing (POCT) to inform production of guidance.

Why was this topic appraised?

 

Sepsis is a potentially life threatening condition, but is often difficult to diagnose (particularly in children). This can lead to over-prescription of antibiotics, which contributes to the global problem of antimicrobial resistance. Procalcitonin POCT can be used in emergency settings to rapidly assess infections (distinguishing between bacterial and viral) in adults and children with suspected sepsis. Facilitating early prescribing decisions could potentially reduce risks associated with delayed diagnosis, and reduce the likelihood of overtreatment.

Topic Exploration Report

TER009 (06.2018)

TER
View PDF

Evidence Appraisal Review

EAR006 (06.2019)

EAR
View PDF

Access our guidance

Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking at our advice and how you intend to use it.
  • We may like to contact you by email to find out more about how you used the documents.

  • This field is for validation purposes and should be left unchanged.